ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells

Abstract Background Most melanoma patients with BRAFV600E positive tumors respond well to a combination of BRAF kinase and MEK inhibitors. However, some patients are intrinsically resistant while the majority of patients eventually develop drug resistance to the treatment. For patients insufficientl...

Full description

Bibliographic Details

Published in:	Molecular Cancer
Main Authors:	Giulia Cesi, Geoffroy Walbrecq, Andreas Zimmer, Stephanie Kreis, Claude Haan
Format:	Article
Language:	English
Published:	BMC 2017-06-01
Subjects:	Melanoma Metabolism RAS/RAF/MEK/ERK pathway NRAS BRAF inhibitors MEK inhibitors
Online Access:	http://link.springer.com/article/10.1186/s12943-017-0667-y